A randomized, double-blind, placebo-controlled clinical study published in the most recent issue of the peer-reviewed Journal of Alternative and Complementary Medicine concludes that the nutritional-based immune health ingredient EpiCor(R) significantly reduces cold- and flu-like symptoms in non-vaccinated individuals, EpiCor manufacturer, Embria(R) Health Sciences, announced today. This study complements a previous clinical study published in Urologic Nursing that showed EpiCor helped to reduce both the incidence and duration of cold and flu symptoms in subjects who had received the flu vaccine.

The study focused on 116 test subjects with no recent history of seasonal influenza vaccination. Test subjects were given either a once- daily 500 mg dose of EpiCor or a placebo over a 12-week period.

Results were measured with in-clinic examinations and serologic analysis at baseline, six and 12 weeks. Participants also utilized a standardized self-report symptom diary. The study found that the subjects who were given EpiCor experienced a statistically significant reduction in the incidence of cold or flu-like symptoms.

"The physical and economic impacts of the common cold and seasonal influenza can be immense, so any additional method that has the potential to reduce the occurrence of associated symptoms for non- vaccinated individuals should definitely be considered and further researched," says Larry Robinson, Ph.D., study co-author and vice president of scientific affairs for Embria Health Sciences.

About Embria Health Sciences and EpiCor
Embria Health Sciences, www.embriahealth.com, combines science and nature to bring high-quality, research-based natural ingredients to the global human nutrition market. Embria's flagship ingredient, EpiCor, is an all-natural product that helps the body balance the immune system and is manufactured using a proprietary technology.
Containing protein, fiber, vitamins, minerals, amino acids, antioxidants and other metabolites that deliver nutritional benefits and support immune health, clinical studies have found EpiCor's immune- balancing properties provide year-round support by helping the body boost or suppress immune response as needed, increases the anti- inflammatory marker IL-10 and activates crucial defense cells (Natural Killer, T-, and B-cells).

For more information on EpiCor, visit embriahealth.com. For an abstract of this study, please contact Amanda Holty at 801.538.0777 or [email protected] .